Tumor News and Research

RSS

New microscope technology may help surgeons work with greater accuracy

Researchers at the University of Arizona have developed a prototype of a new microscope technology that could help surgeons work with a greater degree of accuracy. The new technology, call augmented microscopy, overlays images depicting diagnostic information such as blood flow and cancerous tissue over real images of blood vessels and other tissues and structures being viewed in the microscope.

8 Oct 2015

Myriad Genetics and Tufts Health Plan sign agreement to cover Prolaris® for members with localized prostate cancer

Myriad Genetics, Inc. (NASDAQ: MYGN) has announced that it has signed a three-year contract with Tufts Health Plan through which the plan will provide coverage of Prolaris® for members diagnosed with localized prostate cancer. Prolaris is the first and only biopsy test validated against prostate cancer specific mortality.

7 Oct 2015

Texas Center for Proton Therapy lures top proton talent as Dallas center nears opening

Texas Center for Proton Therapy has announced the hiring of three dedicated radiation oncologists with experience in radiation oncology and proton beam cancer treatment, completing the center’s key medical staff.

7 Oct 2015

Penn Medicine announces $375,000 in new grants to support BRCA-focused research projects

Penn Medicine's Basser Center for BRCA announced $375,000 in new grant funding to support BRCA-focused research projects across the nation. The grants are aimed at advancing the care of patients living with BRCA1 and BRCA2 mutations.

7 Oct 2015

Innovative service model leads to better results for patients with advanced cancer

An innovative service model that partners radiation oncology with palliative care leads to better results for patients, according to a new analysis. The model of care, established at Mount Sinai Medical Center in New York, is one of only a handful in the country. The study will be presented at the upcoming 2015 Palliative Care in Oncology Symposium in Boston.

7 Oct 2015

New diagnostic technology based on computer algorithms can quickly identify source of cancer

In by far the majority of cancer cases, the doctor can quickly identify the source of the disease, for example cancer of the liver, lungs, etc. However, in about one in 20 cases, the doctor can confirm that the patient has cancer—but cannot find the source. These patients then face the prospect of a long wait with numerous diagnostic tests and attempts to locate the origin of the cancer before starting any treatment.

7 Oct 2015

New studies suggest ways to improve cancer care by inhibiting oncogenes, boosting tumor-suppressor activity

Two new studies by cancer scientists at The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC - James) suggest new approaches for treating cancer by inhibiting overactive cancer-promoting genes and by enhancing the activity of sluggish tumor-suppressor genes.

7 Oct 2015

Researchers study effect of immune tolerance on certain cancer risks

For a malignant tumor to form, cancer cells must evade the immune system's attack. Numerous studies have already shown that cancer spreads particularly aggressively if there is an unfavorable balance between suppressing and active immune cells in the tumor microenvironment. "But we didn't know whether this is a consequence of an aggressive tumor or rather its cause," says Rudolf Kaaks, epidemiologist at the German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ).

7 Oct 2015

Rabbit virus can be paired with existing drug to deliver more potent punch to brain tumor cells

A rabbit virus currently being developed for cancer therapy can be paired with one of several existing drugs to deliver a more potent punch to a deadly type of brain tumor cell, researchers have found.

7 Oct 2015

Quest Diagnostics provides PD-L1 IHC 22C3 PharmDx test service for NSCLC patients

Quest Diagnostics, the world’s leading provider of diagnostic information services, today announced that it will provide clinical laboratory testing using the PD-L1 IHC 22C3 PharmDx immunohistochemistry companion diagnostic.

From Quest Diagnostics 7 Oct 2015

Jumping genes: a marker for early cancer diagnosis? An interview with Dr Kazazian

In the genome of every human being, there are about 80-100 active LINE-1s that are capable of mobilizing by a copy and paste mechanism to a new location in the genome.

6 Oct 2015

Novel technique may help women and their oncologists choose options for treating breast cancer

Biomedical engineers have demonstrated a proof-of-principle technique that could give women and their oncologists more personalized information to help them choose options for treating breast cancer.

6 Oct 2015

FDA accepts Sandoz regulatory submission for a proposed biosimilar etanercept

Sandoz, a Novartis company and the global leader in biosimilars, announced today that the US Food and Drug Administration (FDA) has accepted its Biologics License Application (BLA) under the 351 (k) pathway for its proposed biosimilar to Amgen’s US-licensed Enbrel (etanercept) - a tumor necrosis factor alpha (TNF-α) inhibitor

5 Oct 2015

GE unveils different breast cancer tests for different breasts

With an estimated 494,000 new cases per year, breast cancer is by far the most common cancer amongst women across Europe. Particularly affected are women with dense breast tissue because of the difficultly it can cause when trying to detect cancer early using mammography.

5 Oct 2015

Neuroendocrine sequelae common after paediatric optic gliomas

Neuroendocrine sequelae are common following paediatric low-grade gliomas affecting the optic pathway, hypothalamus and suprasellar areas and are influenced by tumour location and treatment choice, a study shows.

1 Oct 2015

Seno completes PIONEER Pivotal Study of non-invasive Imagio breast imaging system

Seno Medical Instruments, Inc., the company pioneering the development of opto-acoustic technology as a new tool to improve the process of diagnosing breast cancer, announced today it has completed the final phase of the company's U.S.-based PIONEER Pivotal Study of the Imagio® breast imaging system.

1 Oct 2015

Multicenter study shows Monteris’ NeuroBlate System improves outcome in brain tumor patients

Monteris Medical today announced recent data demonstrating that newly diagnosed brain tumor patients undergoing procedures with the NeuroBlate System, a minimally invasive robotic laser thermotherapy tool, experienced improved outcomes.

1 Oct 2015

UH researcher investigates two new avenues for detection, treatment of prostate cancer

Prostate cancer is the most commonly diagnosed malignancy and second leading cause of cancer-related deaths among men in the U.S. The challenge with prostate cancer is that the standard treatment methods in the advanced stage of the disease lose effectiveness after about one to two years, leading to recurrence and, ultimately, death. A University of Houston researcher and his team are working to change that.

30 Sep 2015

Aspen Park Pharmaceuticals acquires worldwide rights to APP-111 therapy from Ohio State University

Aspen Park Pharmaceuticals, Inc., a private company, today announced that it has acquired worldwide rights from The Ohio State University, through the Ohio State Innovation Foundation, to APP-111. APP-111 is a first-in-class oral, antitubulin targeting agent for the potential treatment for the form of castration resistant prostate cancer that does not respond or becomes resistant to currently available androgen receptor antagonists like XTANDI (enzalutamide) and testosterone reducing agents like ZYTIGA (abiraterone acetate and prednisone).

30 Sep 2015

Leading cancer researchers address eight 'big questions'

Leading cancer researchers address eight of the "big questions" facing the field as part of the inaugural issue of Trends in Cancer, published by Cell Press.

30 Sep 2015

Tumor News and Research

New microscope technology may help surgeons work with greater accuracy

Myriad Genetics and Tufts Health Plan sign agreement to cover Prolaris® for members with localized prostate cancer

Texas Center for Proton Therapy lures top proton talent as Dallas center nears opening

Penn Medicine announces $375,000 in new grants to support BRCA-focused research projects

Innovative service model leads to better results for patients with advanced cancer

New diagnostic technology based on computer algorithms can quickly identify source of cancer

New studies suggest ways to improve cancer care by inhibiting oncogenes, boosting tumor-suppressor activity

Researchers study effect of immune tolerance on certain cancer risks

Rabbit virus can be paired with existing drug to deliver more potent punch to brain tumor cells

Quest Diagnostics provides PD-L1 IHC 22C3 PharmDx test service for NSCLC patients

Jumping genes: a marker for early cancer diagnosis? An interview with Dr Kazazian

Novel technique may help women and their oncologists choose options for treating breast cancer

FDA accepts Sandoz regulatory submission for a proposed biosimilar etanercept

GE unveils different breast cancer tests for different breasts

Neuroendocrine sequelae common after paediatric optic gliomas

Seno completes PIONEER Pivotal Study of non-invasive Imagio breast imaging system

Multicenter study shows Monteris’ NeuroBlate System improves outcome in brain tumor patients

UH researcher investigates two new avenues for detection, treatment of prostate cancer

Aspen Park Pharmaceuticals acquires worldwide rights to APP-111 therapy from Ohio State University

Leading cancer researchers address eight 'big questions'

Industry Focus eBook - Cell & Gene Therapy (1st Edition) eBook

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News